OUR PARTNERS
OMICURE is the European leader in the field of digital health and precision medicine.
Thanks to its technology which combines an xAI (explainable artificial intelligence) platform which analyses, from solid and liquid biopsies, clinically relevant biomarkers (DNA, RNA and protein profiles), and a large database including the different established treatments against cancer, regularly updated according to global scientific validations, OMICURE markets genomic diagnostic tests.
OMICURE provides oncologists with actionable results, allowing them to choose the treatments best suited to each patient's cancer profile.
BluePrint Genetics is a laboratory specializing in genetic testing.
With its patient-centered approach, BluePrint Genetics offers high-quality genetic testing for 14 medical specialties, combining its state-of-the-art laboratory, the latest sequencing technology, AI-enhanced data analysis tools and techniques, and world-renowned professionals for a comprehensive approach to serving its patients.
BluePrint Genetics provides clinicians and patients with comprehensive, high-quality tools and resources for the diagnosis of genetic conditions across all specialties: pediatrics, cardiology, metabolic disorders, hereditary cancer, nephrology, ophthalmology and more.
PathGroup is the industry leader seeking to identify and understand diseases at the genetic level.
PathGroup focuses on providing accurate, expert diagnostic information to physicians, including personalized medicine and targeted therapies, that help improving patient outcome.
As the field of molecular pathology continues to evolve, new techniques and tests are offered.
PathGroup is not only selective about its choice of tests, but also careful to use most advanced, clinically relevant and approved technologies, so that physicians and their patients get results they can rely on with full confidence.
As the only molecular diagnostics company solely focused on breast cancer, Agendia's groundbreaking genomic testing generates reliable and meaningful clinical data about the unique biology of a woman's breast cancer. Globally backed up by prestigious physicians and institutions, Agendia is shifting the standard of care towards more ideal, personalized treatment. At the genomic level, Agendia provides physicians with a tool that allows the examination of specific genes' activity inside the tumor.
By pairing these insights with clinical factors, we can more comprehensively understand a woman's unique cancer and more confidently plan her next steps.
MammaPrint is FDA-cleared for women of all ages. The device is also CE marked. Mammaprint test is supported by peer reviewed data and highest level of clinical evidence through prospective randomized clinical trial. Mammaprint is recommended by international guidelines such as ESMO, San Gallen, ASCO and NCCN. In addition, Blueprint interrogates 80 genes and identifies the underlying biology of an individual breast cancer. The tumor is then accurately classified as one of three subtypes, which reveal valuable information about its behavior, long-term prognosis, and response to systemic therapy.
geneMAP™ is distibuted in more than 60 countries where it is recognized for its exceptional precision, sensitivity, and speed. To date, over five million tests have been performed, firmly establishing the reliability and speed of geneMAP™ kits in the field of medical genetics.
​
geneMAP™ offers a comprehensive range of specialized genetic tests in hemato-oncology, molecular genetics, molecular microbiology, and digital PCR to meet the needs of biologists for medical diagnostics.
​
Through a rapidly expanding in-house Research and Development service, geneMAP™ is committed to meeting the expectations of its users worldwide, and especially to making molecular testing more accessible by combining superior quality with competitive pricing.
​
Tempus is a cutting-edge laboratory specializing in precision medicine, combining artificial intelligence, genomics, and clinical data analysis to revolutionize disease treatment.
Through advanced genetic sequencing technologies and a machine learning platform, Tempus enables researchers and clinicians to harness complex medical data to develop personalized treatments.
Its state-of-the-art bioinformatics infrastructure accelerates biomarker discovery, enhances clinical trials, and optimizes therapeutic decisions, offering a more targeted and effective approach for patients with cancer, rare diseases, and other complex conditions.